Alyeska Investment Group L.P. acquired a new position in Reata Pharmaceuticals Inc (NASDAQ:RETA) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 91,048 shares of the company’s stock, valued at approximately $2,832,000. Alyeska Investment Group L.P. owned approximately 0.35% of Reata Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in RETA. Geode Capital Management LLC increased its holdings in Reata Pharmaceuticals by 19.5% in the 1st quarter. Geode Capital Management LLC now owns 63,778 shares of the company’s stock worth $1,444,000 after buying an additional 10,397 shares in the last quarter. Renaissance Technologies LLC bought a new stake in Reata Pharmaceuticals in the 1st quarter worth about $559,000. Russell Investments Group Ltd. bought a new stake in shares of Reata Pharmaceuticals during the 2nd quarter valued at about $254,000. Strs Ohio grew its stake in shares of Reata Pharmaceuticals by 220.6% during the 2nd quarter. Strs Ohio now owns 21,800 shares of the company’s stock valued at $689,000 after purchasing an additional 15,000 shares during the period. Finally, Schwab Charles Investment Management Inc. grew its stake in shares of Reata Pharmaceuticals by 44.7% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 27,200 shares of the company’s stock valued at $861,000 after purchasing an additional 8,400 shares during the period. Institutional investors own 29.61% of the company’s stock.

A number of equities research analysts have issued reports on RETA shares. Cowen restated a “buy” rating on shares of Reata Pharmaceuticals in a research note on Tuesday, November 14th. Jefferies Group restated a “buy” rating and set a $44.00 price target on shares of Reata Pharmaceuticals in a research note on Friday, October 6th. Robert W. Baird restated a “buy” rating and set a $47.00 price target on shares of Reata Pharmaceuticals in a research note on Friday, September 1st. Citigroup restated a “buy” rating and set a $78.00 price target (down from $87.00) on shares of Reata Pharmaceuticals in a research note on Wednesday, August 23rd. Finally, Zacks Investment Research upgraded Reata Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 24th. Three analysts have rated the stock with a sell rating and eight have assigned a buy rating to the company’s stock. Reata Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $54.71.

Shares of Reata Pharmaceuticals Inc (NASDAQ:RETA) opened at $22.39 on Wednesday. Reata Pharmaceuticals Inc has a 52 week low of $19.48 and a 52 week high of $40.88. The company has a current ratio of 3.18, a quick ratio of 3.18 and a debt-to-equity ratio of -0.15.

Reata Pharmaceuticals (NASDAQ:RETA) last announced its quarterly earnings data on Monday, November 13th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.39) by ($0.11). The company had revenue of $12.60 million during the quarter, compared to the consensus estimate of $12.54 million. The firm’s quarterly revenue was up .0% compared to the same quarter last year. equities research analysts anticipate that Reata Pharmaceuticals Inc will post -1.91 earnings per share for the current fiscal year.

In related news, Director James Edward Bass acquired 3,888 shares of the business’s stock in a transaction that occurred on Wednesday, November 15th. The stock was bought at an average cost of $24.02 per share, for a total transaction of $93,389.76. Following the purchase, the director now owns 52,089 shares in the company, valued at approximately $1,251,177.78. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 44.00% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “91,048 Shares in Reata Pharmaceuticals Inc (RETA) Acquired by Alyeska Investment Group L.P.” was first published by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.watchlistnews.com/91048-shares-in-reata-pharmaceuticals-inc-reta-acquired-by-alyeska-investment-group-l-p/1760772.html.

Reata Pharmaceuticals Company Profile

Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.

Institutional Ownership by Quarter for Reata Pharmaceuticals (NASDAQ:RETA)

Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.